相关实验视频
Updated: Jan 9, 2026
07:22
Basophil Activation Test for Allergy Diagnosis
Published on: May 31, 2021
9.2K
在慢性自发性疹患者中,对奥马利祖马布反应的生物预测指标
Megan Le1, Tara McCaffrey1, Li Gao1
1Division of Allergy and Clinical Immunology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Md.
The journal of allergy and clinical immunology. In practice
|November 30, 2025
概括
患有慢性自发性疹和特定负生物预测因子的患者,如低IgE,阳性CU指数 (CUI) 或低血胺含量 (BHC),对奥马利祖马布治疗的反应较差.
科学领域:
- 免疫学 免疫学 免疫学
- 皮肤病学 皮肤病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 奥马利祖马布是一种治疗慢性自发性疹 (CSU) 的药物.
- 对奥马利祖马布反应的负生物预测器包括低基线IgE,阳性CU指数 (CUI) 测试和基底 (血液中低胺含量 - BHC).
研究的目的:
- 评估这些负生物预测因子的患者是否对奥马利祖马布治疗的反应减弱.
- 在CSU患者中确定奥马利祖马布治疗结果的预测因素.
主要方法:
- 对3项III期临床试验的回顾性分析,涉及用奥马利祖马布治疗的抗胰岛素耐药性CSU患者.
- 在12周后检查了基线生物预测器 (IgE,CUI,BHC) 和症状控制 (疹活动评分7 - UAS7) 之间的关联.
- 统计分析包括千平方,逻辑回归和接收器操作特征 (ROC) 分析.
主要成果:
- 总共分析了363名受试者;266人有BHC数据.
- 在12周症状控制不佳 (UAS7 > 6) 的受试者更有可能具有低基线IgE (50%),阳性CUI (55%) 或低BHC (55%).
- 阳性CUI显著预测症状控制不良 (OR,2.54;P = .0002). ROC分析显示BHC为6.4 ng/mL,区分非响应者. 低IgE与低BHC结合预测不响应 (P = .040).
结论:
- 阳性CUI,低BHC或低IgE和低BHC的组合与CSU患者对奥马利祖马布反应较差的可能性更高.
- 这些生物预测器可以帮助预测CSU中的奥马利祖马布治疗结果.
相关概念视频
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K
02:06Allergic Reactions
31.9K
Overview
31.9K
01:19Antiasthma Drugs: Leukotriene Modifiers
1.7K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.7K
01:27Allergic Drug Reactions
1.3K
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
1.3K